Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    TopAbstracts in Diabetes 07/08/2008 - (DGNews)
    Elevated Levels of Liver Protein Associated With Increased Risk for Diabetes - (DGNews)
    TopAbstracts in Diabetes 07/01/2008 - (DGNews)
    Dietary Adherence Improves Glucose Control in Children With Type 1 Diabetes - (DGNews)
    TopAbstracts in Diabetes 06/24/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Diabetes
    • Overactive Bladder: A Case-Based Approach to Managing Symptoms While Optimising Outcomes
    • Practical Approach to Managing Urinary Frequency and Urge Incontinence in Younger Patients
    • Managing Older Patients With Urinary Symptoms and Comorbidities
    • Diabetic Peripheral Neuropathies
      Treat to Success: The Pharmacist's Role in the Treatment of Patients With Type 2 Diabetes

      Webcasts/CME archive

       Recent cases - Diabetes
        New Onset Diabetes Complicated by Haemolysis and Rhabdomyolysis: A Case Report and Review of the Literature
        Diabetic Control and Atypical Antipsychotics: A Case Report
        Treatment with Pioglitazone Induced Significant, Reversible Mitral Regurgitation
        An Elderly Patient with Sarcoidosis Manifesting Panhypopituitarism with Central Diabetes Insipidus
        Melioidosis Presenting as Genitourinary Infection in Two Men with Diabetes

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Repaglinide Outperforms Nateglinide for Reducing Hemoglobin A1c and Fasting Plasma Glucose in Type 2 Diabetes: Presented at AACE

        By Maury M. Breecher, PhD, MPH

        SAN DIEGO, CA -- May 21, 2003 -- Repaglinide monotherapy was significantly more effective than nateglinide monotherapy for reducing hemoglobin A1c (HbA1c), and fasting plasma glucose (FPG) levels in patients with type 2 diabetes, according to a multicenter trial.

        Results were presented on May 16th here at the American Association of Clinical Endocrinologists 12th Annual Meeting and Clinical Congress.

        One hundred and forty patients took part in this 16-week, open-label, randomized, parallel-group study. Participants started with HbA1c values between 7% and 12% during a previous treatment of diet and exercise alone.

        Both repaglinide and nateglinide had similar postprandial glycemic effects, but repaglinide monotherapy at a final dose of 6 mg/day, was clinically and statistically more effective than nateglinide monotherapy at a final dose of 360 mg/day, in reducing FPG and HbA1c values, according to lead study author Mohammed F. Saad, MD, Los Angeles Diabetes Center, Alhambra, Calif.

        The 71 patients on repaglinide started with a baseline HbA1c of 8.9%, and had a mean change of –1.57 (P=0.002), compared with 69 patients on nateglinide who also had a baseline mean of 8.9, but had a mean change of –1.04 at the study end point. The repaglinide group had a –57 mg/dL mean change in FPG, and the nateglinide group had a –18 mg/dL change (P<0.001).

        Minor hypoglycemic episodes occurred in 7% of repaglinide patients, but none of nateglinide patients. No episodes of major hypoglycemia were reported in either group.

        The researchers concluded that repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing HbA1c and FPG values in patients with type 2 diabetes, previously treated with diet and exercise.

        This study was sponsored by Novo Nordisk Pharmaceuticals, Inc., Princeton, NJ.


        [Study title: Repaglinide vs. Nateglinide Monotherapy: A Randomized, Multicenter, Open-Label Study. Abstract 44]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send